Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.
Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, Dima D, Afrough A, Kaur G, Davis JA, Herr M, Hashmi H, Forsberg P, Sborov D, Anderson LD Jr, McGuirk JP, Wagner C, Lieberman-Cribbin A, Rossi A, Freeman CL, Locke FL, Richard S, Khouri J, Lin Y, Patel KK, Kumar SK, Hansen DK.
Zanwar S, et al. Among authors: davis ja.
J Hematol Oncol. 2024 Jun 6;17(1):42. doi: 10.1186/s13045-024-01555-4.
J Hematol Oncol. 2024.
PMID: 38845015